Compare GROW & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | CGTX |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 110.8M |
| IPO Year | 1995 | 2021 |
| Metric | GROW | CGTX |
|---|---|---|
| Price | $2.54 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 16.6K | ★ 833.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $23,850,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.18 | $0.22 |
| 52 Week High | $3.65 | $3.83 |
| Indicator | GROW | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 55.33 |
| Support Level | $2.51 | $1.19 |
| Resistance Level | $2.56 | $1.36 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 12.93 | 64.41 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).